{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-017141","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.347910+00:00","generated_at":"2026-06-04T03:34:20.345003+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Roivant reports positive Phase 2 NIU data; authorizes $1.5B buyback, repurchases Sumitomo's 9% stake","bullets":["Phase 2 NEPTUNE: brepocitinib 45mg arm had 29% Treatment Failure at week 24 (vs 44% for 15mg), best observed in NIU studies.","All secondary endpoints positive; 43% of patients with baseline macular edema achieved resolution by week 24 on 45mg.","Board authorized up to $1.5B share repurchase; $648.4M to buy Sumitomo's 71.3M shares at $9.10, reducing shares outstanding by ~9%.","Phase 3 program in NIU to start H2 2024; Phase 3 dermatomyositis study fully enrolled Q3 2024, data expected 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-017141","json":"https://secwatch.observer/filing/0001140361-24-017141.json","markdown":"https://secwatch.observer/filing/0001140361-24-017141.md","text":"https://secwatch.observer/filing/0001140361-24-017141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124017141/0001140361-24-017141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124017141/ef20025692_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:34:20.345003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}